TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
Mayo Clinic
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
Dana-Farber Cancer Institute
Sanofi
City of Hope Medical Center
University of Washington
University of Chicago
Mayo Clinic
University of Southampton
Amgen
Celldex Therapeutics
National Institutes of Health Clinical Center (CC)
Sunnybrook Health Sciences Centre
National Cancer Institute (NCI)
Seagen Inc.
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Novartis
University College, London
Merck Sharp & Dohme LLC
University of Washington
Royal Marsden NHS Foundation Trust
Ohio State University Comprehensive Cancer Center